Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To the Editor: In their study on rhabdomyolysis
in patients treated with lipid-lowering drugs, Dr Graham and colleagues1 reported that, compared with statin monotherapy, the
use of fibrates alone was associated with a 5.5-fold increase in the risk
of rhabdomyolysis requiring hospitalization and the combined use of a statin
and fibrate resulted in an additional increase in this risk, especially in
older patients with diabetes mellitus. These risks were most pronounced for
cerivastatin compared with other statins, both when it was used as monotherapy
and when used in combination with a fibrate.
Tenenbaum A, Fisman EZ, Motro M. Rhabdomyolysis and Lipid-Lowering Drugs. JAMA. 2005;293(12):1448-1449. doi:10.1001/jama.293.12.1448-a